Vir Biotechnology, Inc.
Clinical trials sponsored by Vir Biotechnology, Inc., explained in plain language.
-
New drug combo shows promise against rare liver virus
Disease control OngoingThis study tests two experimental drugs, VIR-2218 and VIR-3434, in 95 adults with chronic hepatitis D, a serious liver infection. The goal is to see if the drugs can lower the virus to undetectable levels and improve liver function. Participants must already be on standard hepati…
Phase: PHASE2 • Sponsor: Vir Biotechnology, Inc. • Aim: Disease control
Last updated Jun 22, 2026 12:08 UTC
-
New drug duo aims to control hard-to-treat hepatitis delta
Disease control OngoingThis phase 3 study tests whether a combination of two drugs, tobevibart and elebsiran, can control chronic hepatitis delta better than waiting for treatment. About 124 adults with the infection will receive either the combo therapy or delayed treatment. The goal is to see if the …
Phase: PHASE3 • Sponsor: Vir Biotechnology, Inc. • Aim: Disease control
Last updated Jun 22, 2026 12:04 UTC
-
New drug duo takes on rare liver virus in head-to-head trial
Disease control OngoingThis study tests whether a combination of two experimental drugs (Tobevibart and Elebsiran) works better than the current treatment Bulevirtide for people with chronic hepatitis D, a serious liver infection. About 100 adults with stable liver disease will receive either the combo…
Phase: PHASE2 • Sponsor: Vir Biotechnology, Inc. • Aim: Disease control
Last updated Jun 22, 2026 12:03 UTC